A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
Public ClinicalTrials.gov record NCT02727699. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease. Subjects will be randomized to receive either 10mg once daily Xanamem or Placebo at a 1:1 ratio in a double-blinded fashion.
Study identification
- NCT ID
- NCT02727699
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 185 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 23, 2017 (Actual)
- Primary completion
- Mar 15, 2019 (Actual)
- Completion
- Mar 15, 2019 (Actual)
- Last update posted
- Feb 3, 2025
2017 – 2019
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Tucson Neuroscience Research, LLC | Tucson | Arizona | 85710 | — |
| National Research Institute | Los Angeles | California | 90057 | — |
| PCND Neuroscience Research Institute | Poway | California | 92064 | — |
| Pacific Research Network, Inc. | San Diego | California | 92103 | — |
| Research Alliance Inc. | Clearwater | Florida | 33756 | — |
| The Neurology Research Group, LLC | Miami | Florida | 33186 | — |
| Compass Research LLC | Orlando | Florida | 32806 | — |
| IMIC, Inc. | Palmetto Bay | Florida | 33157 | — |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30331 | — |
| NeuroStudies.Net, LLC | Decatur | Georgia | 30033 | — |
| The NeuroCognitive Institute | Mount Arlington | New Jersey | 07856 | — |
| Richmond Behavioral Associates | Staten Island | New York | 10312 | — |
| PMG Research of Rocky Mount, LLC | Rocky Mount | North Carolina | 27804 | — |
| The Clinical Trial Center | Jenkintown | Pennsylvania | 19046 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02727699, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 3, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02727699 live on ClinicalTrials.gov.